NASDAQ:INSM
Insmed (INSM)
Financials 
Technical Analysis 
Aug 13, 2026, 12:00 amThis summary was created by AI, based on 1 opinions in the last 12 months.
Insmed (INSM-Q) has experienced a remarkable rise of 152% over the past year, largely driven by the FDA's approval of one of its leading drugs aimed at treating a lung condition. This approval has positioned the company as a significant player in the biotech sector, generating excitement among investors. However, the stock faced a setback, pulling back 18% last month following disappointing trial results for another drug, raising questions about its future growth trajectory. Experts suggest that while ups and downs are common in the sector, Insmed remains a company worth monitoring closely. Overall, investors should consider the potential risks and rewards before making decisions regarding their investments in Insmed.
- «
- ‹
- 1
- ›
- »
Popular Articles
Insmed (INSM) Frequently Asked Questions
What is Insmed stock symbol?
Insmed is a American stock, trading under the symbol INSM (previously INSM-Q on Stockchase) on the NASDAQ (INSM). It is usually referred to as NASDAQ:INSM or INSM
Is Insmed a buy or a sell?
In the last year, no analyst issued a Buy, Sell, or Hold rating on INSM (previously INSM-Q on Stockchase) on Stockchase. Read the latest expert commentary for Insmed .
Is Insmed a good investment or a top pick?
Insmed was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Insmed .
Why is Insmed stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Insmed .
Is Insmed worth watching?
Insmed is covered by Stockchase experts and is worth watching.
What is Insmed stock price?
On 2026-08-13, Insmed (INSM) stock closed at a price of $126.33.
Up 152% last year. They got FDA approval for one of their top drugs last year to treat a lung condition. It pulled back 18% last month due to a disappointing trial result in a drug. Worth watching this.